Abstract: The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor or expression inhibitor as an active ingredient.

Abstract: Disclosed are a cosmetic composition for improving anti-oxidation, anti-inflammation and atopic skin by using fermented liquid of black tea as an effective ingredient and a method of preparing the same. The cosmetic composition includes the fermented black tea liquid obtained by primarily fermenting black tea with saccharomyces, secondarily fermenting the black tea with gluconacetobacter and tertiarily fermenting the black tea with bacillus.

Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

Abstract: There is provided a method for treating or reducing an anticancer agent-induced nephrotoxic injury, the method comprising the step of administering a Y1 receptor activator in an amount effective to treat or reduce the anticancer agent-induced nephrotoxic injury in a subject. Further, there is provided a method for screening an agent for treating or reducing an anticancer agent-induced nephrotoxic injury, the method comprising (a) applying a candidate material to a test sample of renal tissues or cells; and (b) identifying a Y1 receptor signaling in the test sample of renal tissues or cells.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as an active ingredient. The neuropeptide Y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a Y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent. When a haematopoietic stem cell is released into the blood, the number of osteoclasts which induce an osteoporotic lesion by differentiation from the haematopoietic stem cell decreases, and thus progression of a bone erosion caused by osteoclasts can be prevented. Accordingly, the neuropeptide Y which is an active ingredient of the composition of the present invention is useful as a therapeutic agent for osteoporosis.

Abstract: A method for treating a neurodegenerative disease and depression, the method comprising administering to a subject in need thereof an effective amount of a composition comprising derivatives of 2-amino-2-(1-dodecyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol as an active ingredient.

Abstract: Provided is a composition containing neuropeptide Y for inhibiting side effects of anticancer agents. The neuropeptide Y of the present invention exhibits an effect of mitigating side effects, especially bone marrow injury and neurological disorders, occurring due to the administration of anticancer agents, and thus may be useful as an anticancer adjuvant which may mitigate side effects of anticancer agents and enhance the effect of anticancer agents.

Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 15 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 15 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 15 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as an active ingredient. The neuropeptide Y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a Y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent. When a haematopoietic stem cell is released into the blood, the number of osteoclasts which induce an osteoporotic lesion by differentiation from the haematopoietic stem cell decreases, and thus progression of a bone erosion caused by osteoclasts can be prevented. Accordingly, the neuropeptide Y which is an active ingredient of the composition of the present invention is useful as a therapeutic agent for osteoporosis.

Abstract: A distributed generation system and method of using a rental article having a flexible thin film solar cell are disclosed. The distributed generation system of a rental article using a flexible thin film solar cell can include: a rental article which generates electric energy from collected solar energy; and a station which is positioned in a space for renting and returning the rental article, and distributes and transmits electric energy provided from the rental article to a power demand target.